IPP Bureau
Fujifilm collaborates with DCC Animal hospital for diagnostics support
By IPP Bureau - December 07, 2021
Fujifilm India will be providing healthcare Imaging devices and equipment’s to increase the standards of the veterinary care in India.
Hilleman Laboratories invests US $ 58 mn to establish vaccine hub in Singapore
By IPP Bureau - December 07, 2021
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Wipro-GE unveils B2B e-commerce platform for medical equipment
By IPP Bureau - December 07, 2021
It is an extension of GE Healthcare’s online service delivery enterprise Service Shop
Study shows Glaxo-Vir drug works against Omicron mutations
By IPP Bureau - December 07, 2021
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Early management of Covid-19 key to reduce mortality and hospitalisation
By IPP Bureau - December 06, 2021
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
AWS partners with Pfizer to accelerate drug development
By IPP Bureau - December 06, 2021
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Roche develops tests to identify Omicron variant
By IPP Bureau - December 06, 2021
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
Lilly's bamlanivimab with etesevimab authorized for emergency use in Covid-19 patients under 12
By IPP Bureau - December 06, 2021
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Roche to launch SARS-CoV-2 and flu A/B Rapid Antigen Test in countries accepting the CE mark
By IPP Bureau - December 06, 2021
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
J&J booster after the two-dose Pfizer-BioNTech vaccine increases antibody and T-cell responses
By IPP Bureau - December 06, 2021
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Ophthalmologists converge in Chennai to discuss latest innovations
By IPP Bureau - December 05, 2021
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
Narayana Hrudayalaya to open a hospital in Punjab
By IPP Bureau - December 05, 2021
The hospital is scheduled to open in 2024 with a bed capacity of 225
Lupin and Biomm tie-up for pegfilgrastim in Brazil
By IPP Bureau - December 05, 2021
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
SPARC to licence Biomodifying’s IP
By IPP Bureau - December 05, 2021
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Morpen gets U.S. FDA approval for Fexofinadine
By IPP Bureau - December 05, 2021
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
